Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.34 |
| ▸ | KHK | P50053 | 1/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.31 |
| ▸ | F2 | P00734 | 1/20 | 0.31 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.31 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.30 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30279015 | 1.00 | KDM4E (0.35) | KDM4EHTTPTGER4KHKUSP30 | |
| SCHEMBL11935409 | 1.00 | KDM4E (0.35) | KDM4EHTTPTGER4KHKUSP30 | |
| SCHEMBL13462757 | 1.00 | KDM4E (0.35) | KDM4EHTTPTGER4KHKUSP30 | |
| SCHEMBL25039786 | 1.00 | KDM4E (0.35) | KDM4EHTTPTGER4KHKUSP30 | |
| SCHEMBL25040029 | 0.92 | KDM4E (0.36) | KDM4EHTTPTGER4KHKUSP30 | |
| SCHEMBL30279292 | 0.92 | KDM4E (0.36) | KDM4EHTTPTGER4KHKUSP30 | |
| SCHEMBL13462796 | 0.91 | KDM4E (0.36) | KDM4EHTTPTGER4KHKUSP30 | |
| SCHEMBL11935239 | 0.91 | KDM4E (0.36) | KDM4EHTTPTGER4KHKUSP30 | |
| SCHEMBL13438928 | 0.91 | KDM4E (0.36) | KDM4EHTTPTGER4KHKUSP30 | |
| SCHEMBL30279042 | 0.90 | PTGER4 (0.36) | KDM4EPTGER4KHKLRRK2F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9150507-B2 | Amine derivative having NPY Y5 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2015-10-06 | — | — | US | disclosed |
| US-9150507-B2 | Amine derivative having NPY Y5 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2015-10-06 | — | — | US | disclosed |
| US-20100063027-A1 | Amine Derivative Having NPY Y5 Receptor Antagonistic Activity | SHIONOGI & CO., LTD. (JP) | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063027-A1 | Amine Derivative Having NPY Y5 Receptor Antagonistic Activity | NPY5R, NPY1R, NPY2R | KDM4E 1765/4885HTT 1625/4885PTGER4 935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.